- Open Access
Quaternary diagnostics scheme for mucolipidosis II and detection of novel mutation in GNPTAB gene
Journal of Genetic Engineering and Biotechnology volume 19, Article number: 111 (2021)
Mucolipidosis II (ML II α/β) is an inherited lysosomal storage disorder caused by deficiency of GlcNAc-phosphotransferase enzyme and results in mis-targeting of multiple lysosomal enzymes. Affected patients are characterized by skeletal deformities and developmental delay. Homozygous or compound heterozygous mutations in GNPTAB gene are associated with the clinical presentation. This is the first study to characterize the underlying genetics of ML among a cohort of Egyptian patients. ML II diagnosis established by clinical assessment, biochemical evaluation of enzymes, electron microscopy examination of gingival inclusion bodies, and molecular study of GNPTAB gene using targeted next-generation sequencing panel in 8 patients form 8 unrelated Egyptian families.
Sequencing revealed 3 mutations in GNPTAB gene; 1 novel frame-shift mutation in exon 19 (c.3488_3488delC) and 2 previously reported mutations (c.1759C>T in exon 13 and c.3503_3504delTC in exon 19). All patients were homozygous for their corresponding mutations and the parents were consanguineous.
According to the established quaternary diagnostic scheme, ML II was the final diagnosis in eight patients. The most common mutation was the frame shift c.3503_3504delTC mutation, found in 5 patients and associated with a severe phenotype.
Mucolipidosis types II (ML II α/β) is an inherited lysosomal storage disorder known as I-cell disease (OMIM# 252500). ML II α/β is caused by deficiency of the uridine diphosphate (UDP)-N-acetylglucosamine: lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase; EC 22.214.171.124) [12, 16]. This membrane-bound enzyme is responsible for the initial synthesis step of Mannose-6-Phosphate (M6P). Without M6P, newly synthesized lysosomal hydrolases processing and packaging are impaired and are misdirected and secreted into extracellular spaces. An attenuated form of the disease was also reported as mucolipidosis type III (ML III). ML III is classified into 2 subtypes: ML III α/β (OMIM# 252600, also known as Pseudo-Hurler polysdystrophy) and ML III γ (OMIM# 252605) [27, 29].
They are rare genetically related inherited disorders of lysosomal metabolism. Their combined frequency is about 1:422,000 live births. Worldwide estimates showed that ML II occurs in about 1 in 100,000 to 400,000 individuals . The estimated incidence of ML is 2.5 and 10 cases per 1,000,000 live births across the world [15, 17]. In the young founder population of the north-eastern region of Quebec [Saguenay–Lac-Saint-Jean (SLSJ)], ML II prevalence reached of 1/6184 at birth with an estimated carrier rate of 1/39 .
ML II α/β represents the most severe form of the disease. Clinical symptoms of ML II α/β usually start at birth and sometimes it is evident prenatally; the disease course is very aggressive. ML II α/β patients are characterized by coarse facial features, dysostosis multiplex—like deformities, hypertrophic gingiva, and delayed psychomotor development. Cardiopulmonary complications are the principal cause of death during the first decade of life in ML II α/β patients [3, 11, 19, 21, 28].
The GlcNAc-phosphotransferase enzyme is a hexameric complex (2 α, 2 β, and 2 γ subunits) encoded by 2 genes. The α and β subunits are encoded by GNPTAB gene (MIM: 607840) which contains 21 exons and span a genomic region of 85 kb on chromosome 12q23.3. The protein encoded has 1256 amino acids in length with 144 kDa molecular mass for α/β precursor. Mutations in this gene were found to be responsible for ML II α/β and a more attenuated form; ML III α/β. While mutations in the GNPTG gene (MIM: 607838) at chromosome 16p13.3, which encodes the γ subunit were associated with ML III γ .
Almost 25% of the known GNPTAB mutations are located in the 1112 bp exon 13. The majority of the mutations (72%) were found in individual families; only 25 GNPTAB mutations (10%) were identified in more than two families. The most prevalent GNPTAB mutation c.3503_3504del was identified in 131 individuals and does not cluster geographically .
The study aimed to identify for the first time the molecular pattern of ML II among clinically suspected patients in order to confirm the diagnosis by molecular analysis and to establish a four-stage diagnostic scheme including clinical evaluation, electron microscopy examination, biochemical, and molecular studies. This would provide the more accurate diagnosis and prognosis, prenatal diagnosis, and family counseling.
Ethics approval and consent to participate
The Medical Research Ethics Committee at the host research institute approved the study protocol and results. Written informed consents were obtained from legal guardians of the participants according to guidelines of the Medical Research Ethics Committee.
Eight patients from eight unrelated families were referred from the Limb Malformations & Skeletal Dysplasia Clinic (LMSDC) and Biochemical Genetics Department. The patients were 5 males and 3 females of age ranged from 3 months to almost 4 years. Two amniotic fluid samples obtained from pregnant mothers of two unrelated patients included in the study were subjected to molecular analysis. Parents’ consanguinity was confirmed in all studied families.
Lysosomal enzyme analysis
The β-Hexosaminidase-A enzyme activity was measured in plasma isolated from fresh peripheral blood samples using fluorogenic substrate 4-methylumbelliferyl-6-sulfo-2-acetamido-2-deoxy-β-d-glucopyranoside. The assay was performed according to the protocol proposed by . The reference range for this enzyme was 50–200 μmol/l/h.
Electron microscopy examination
Oro-dental examination started with clinical evaluation of the mouth. Gingival biopsy was then examined by bright field illumination in Zeiss microscope using toluidine blue or methylene blue stain. Ultrathin section obtained from the selected area of the specimen was then stained with uranyl acetate and citrate and examined under the transmission electron microscope.
For each participant, 3–5 ml of peripheral (venous) blood samples were withdrawn and transferred immediately to either PAXgene specific blood collecting tubes or polypropylene tubes containing 0.5 M EDTA (pH 8.0, violet cap) and mixed thoroughly to prevent clotting and to stop nuclease activity.
Genomic DNA was extracted from peripheral blood leukocytes. DNA concentration and purity were determined using NanoDrop® 2000 (Thermo Scientific, USA) and DeNovix® (DeNovix Inc. USA) to quantify the dsDNA.
The whole GNPTAB gene and the intervening sequences were sequenced by MiSeq® Sequencing System within a costumed panel of genes related to inherited genetic disorders. This panel was designed upon request by Illumina, USA. It consisted of 25 genes including GNPTAB gene. The library was prepared using the TruSeq® Custom Amplicon v1.5 Reagent kit (Illumina, USA). GNPTAB mutations detected were then confirmed by Sanger sequencing using ABI 3500 Genetic Analyzer (Applied Biosystems, USA) for both patient and their parents if available.
DNA was extracted from 20 cc amniotic fluid samples using a GeneJET Whole Blood Genomic DNA Purification Mini Kit (Thermo Scientific, USA) according to the manufacturer’s protocol, and then, Sanger sequencing was used to detect the mutation sites of the probands. Sequencing chromatograms visualized by Finch TV software and aligned with GNPTAB gene reference sequence (NM_024312.4) to identify nucleotide variations. ENTPRISE-X tool was used for in silico analysis of detected mutations.
This study is considered as case-series study, and such study type is more descriptive than being analytical so that no statistical analysis is needed.
All patients were provisionally diagnosed as mucolipidosis type II according to their clinical manifestations with dysostosis multiplex associated with biochemical increase in the extracellular activity of β-Hexosaminidase-A enzyme above reference range in accordance with specific electrophoretic separation pattern of urinary glycosaminoglycans (GAGs), and finally the identification of inclusion bodies in electron microscopy grids for the gingival biopsy. Only two patients deceased before completing their clinical assessment; however, ML was suspected according to the biochemical and electron microscopy (E.M.) findings.
Urinary GAGs were high for age with specific pattern in electrophoretic separation different from that of MPS.
Clinical and oro-dental results
The first signs and symptoms were noted either prenatally or at birth in most cases mainly in the form of coarse facies, delayed milestones, and progressive skeletal deformities (Figs. 1, 2, 3, and 4). Clinical data of 6 patients were summarized in Table 1. Certain clinical data of the remaining two patients (no. 5 and no. 8) were not available, as they deceased soon after referral.
All patients were presented with dysostosis multiplex. Detailed skeletal survey has shown progressive abnormal skull shape in patient nos. 1, 3, and 6; oar-shaped ribs in patient nos. 3 and 4; bilateral lower limb bowing in patient nos. 6 and 7; in addition to kyphoscoliosis noted in patient nos. 3 and 6, and pectus carinatum in patient no. 7. Two patients had small head circumference, nos. 2 and 4. Mild brain atrophy could be elucidated from CT scans of patient nos. 6, 7, and 8. Cardiopulmonary complications including mitral valve prolapse, mitral valve regurgitation, atrial septal defect secundum, recurrent upper respiratory tract infections, dilated left ventricle, and pulmonary hypertension were evident in the echocardiography. Three families (nos. 1, 2, and 4) had a history of previously died sibling due to respiratory distress.
General oro-dental examination of the patients showed prominent long philtrum, thin lips, prominent premaxilla, retrognethia of maxilla, broad jaws with thick alveolar ridges, and gingival hyperplasia in all patients.
Electron microscopy examination
The ultrastructure examination with electron microscopy showed the characteristic picture of ML in seven patients with the presence of several inclusion bodies (Fig. 5A–C). Increased number of collagen fibers, widening of the intracellular spaces which are filled with lipid, inter- and intracellular large vacuoles of mucoid and lipid material varying in size with multiple nucleoli, and enlarged nucleus filling almost the cytoplasm with nuclear invagination.
Lysosomal enzyme analysis
β-Hexosaminidase-A enzyme activity assay ranged from 263 to 702 nmol/l/h (495.5 ± 185) for 8 patients (Table 2). All the results were above the normal range of GNPTAB enzyme activity (n: 50–200 nmol/l/h.).
NGS analysis of GNPTAB gene
Mutations of GNPTAB gene were detected in 8 unrelated patients. All patients were homozygous for their corresponding mutations (Table 2). Interpretation and bioinformatics analysis of the 8 different variants detected has shown that five of which were benign and three were pathogenic and disease causing. The five benign variants were 2 synonymous variants rs10778148 (c.1932A>G) and rs4764655 (c.18G>A), one intronic splice site SNV (c.3135+5T>C), one intronic SNV (c.3336-25T>C), and one intronic deletion (c.1613-25delA).
However, the 3 pathogenic variants were a previously reported nonsense mutation in exon 13 c.1759C>T (p.R587X) that was detected in two patients. It caused the production of an inactive truncated precursor GNPTAB protein . In both families, parents were heterozygous each for the corresponding mutation. The same mutation was also screened in two amniotic fluid samples (AF) one from each family. Wild-type sequences of exon 13 were detected in the AF sample from patient no. 1’s family. However, AF sample of patient no. 2’s family showed an affected sibling (Fig. 6A–C).
The second pathogenic variant was a frameshift deletion in exon 19, c.3503_3504delTC (p.L1168QfsX5), identified in 5 patients. It was previously reported as disease causing mutation for both ML II and Stuttering [9, 16]. It is resulted in frame shift of open reading frame (ORF) of the gene and premature stop codon is generated (Fig. 6D–F).
The third pathogenic variant was a novel single base deletion (c.3488_3488delC) in exon 19, causing a frame shift mutation that changed threonine at position 1163 into lysine and led to a premature stop codon two amino acids away from the deletion site (p.T1163KfsX2) (Fig. 6G–H). Analysis with ENTPRISE-X was carried out; an algorithm for predicting human disease-associated frameshift and nonsense mutations. It scored the novel mutation 0.71912 which classifies it as a deleterious disease-causing or disease-damaging mutation (Fig. 7). Comparing the ENTRPRISE-X scores for both frameshift mutations, the novel mutation p.T1163KfsX2 scored higher than the reported p.L1168QfsX5 mutation (0.68407). This confirms the pathogenicity of the mutation.
Sanger sequencing analysis
PCR amplification and sequencing were performed for exons 13 and 19 of GNPTAB gene to confirm the mutations detected by NGS.
The novel detected variant of GNPTAB gene in exon 19 was submitted to ClinVar database and gained accession number SCV000891127.1 (National Center for Biotechnology Information. ClinVar; Variation ID 623268, https://preview.ncbi.nlm.nih.gov/clinvar/variation/623268 (accessed April 22, 2019)).
Mucolipidosis type II (ML II) is an autosomal recessive lysosomal storage disorder with disturbed metabolism of many mucopolysaccharides or GAGs giving rise to clinical features similar to those encountered in patients with mucopolysaccharidoses (MPS). It resulted from impaired trafficking of lysosomal hydrolases to lysosomes due to total or near total deficiency of GlcNAc-phosphotransferase enzyme [3, 8, 12, 29].
Our study aimed mainly at establishing a diagnostic tool to confirm ML diagnosis in suspected patients. The diagnosis is confirmed by the detection of pathogenic variants (mutations) which affect the function of the GNPTAB gene product (protein), but we do not study polymorphic markers.
This study identifies the first GNPTAB mutations in eight Egyptian patients with ML II. The studied patients were selected based on three main inclusion criteria: their clinical presentations, oro-dental examination including E.M. picture of gingival biopsy, and β-Hexosaminindase-A enzyme activity assay. The whole 21 exons of GNPTAB gene were sequenced in 8 patients. Three different mutations were detected in exons 13 and 19; one of which was novel (p.T1163KfsX2 in exon 19).
Plante et al. linked the ML II phenotype observed in the probands to the deleterious effect of c.3503_3504delTC (p.L1168QfsX5) deletion mutation of the GNPTAB gene. It was described as a null allele, which means that protein coded (p.L1168QfsX5) do not produce any GlcNAc-phosphotransferase activity. The result of 2 nucleotide (CT) deletions from a repeating CTCT sequence may have caused a mismatch-repair error. The frameshift truncates the enzyme at amino acid 1171 in the β-subunits. Fibroblasts of patients homozygous for his mutation showed very low value of ≤ 1% GlcNAc-phosphotransferase activity. Thus, homozygous c.3503_3504delTC mutation is responsible for the phenotype presentation of MLII disease [14, 18].
In the majority of the studied populations, the (c.3503_3504delTC; p.L1168QfsX5) mutation of GNPTAB gene is the most frequent ML II causing mutation. It was the only detected mutation among 27 ML II obligatory carriers in French Canada . In Italy and the USA, this mutation represented 51% (of 38 patients) and 22% (of 61 patients) of ML II/III α/β patients, respectively. In a study group of 21 ML II patients, Arabs, Turkish, and Irish origin of Israel and Palestinian Arabs, only 12 patients had p.L1168QfsX5 mutation [2, 14]. Also, it was detected in 51.1% of mutant alleles in homozygous pattern within a cohort of 14 ML II patients including 12 Italian, 1 Bangladeshi, and 1 Argentinian. In ML II Portuguese patients, it was the most frequent GNPTAB mutation found, accounting for 45% of the mutant alleles detected in the Portuguese series [6, 23]. It was also reported in Indian patients twice, in 2014 and in 2016 [1, 22].
Studies concluded that (c.3503_3504delTC; p.L1168QfsX5) could have a potential founder ancestor or molecular lesion. The origin and spread of the pathogenic c.3503_3504delTC variant was conducted through a worldwide haplotype diversity assessment including samples bearing the mutation. It inferred that they are descendants from a single founder ancestor probably in a peri-Mediterranean region out of Europe . Nevertheless, this conclusion does not apply for the Chinese population. Where the majority of Chinese patients reported mutations were located in exon 13 or its intronic flanking regions .
Our results conformed c.3503_3504delTC mutation frequency to the previously published ones. The mutation was detected in 5 unrelated patients; 3 males and 2 females. It was found in homozygous pattern in more than half of our studied group (10/16 alleles). All of them were offspring of consanguineous marriages. Their symptoms mostly denoted at birth or shortly after. Four of the patients presented with typical ML symptoms including short stature, coarse facies, gingival hypertrophy, and variable degrees of brain affection.
The nonsense mutation c.1759C>T (p.R587X) was reported in two patients, nos. 1 and no. 2, both had severe manifestations of ML that were evident very early in life, and in one amniotic fluid sample for one of the families. The family history of both patients showed first cousin consanguinity between parents and a history of similarly affected died siblings. Moreover, one of the two patients died at the age of 3 months suggesting the association of severe ML II phenotype. In 2010, Cathey et al. reported the nonsense p.R587X mutation in a heterozygous pattern, co-occurring with a heterozygous frame-shift mutation in the same exon in USA and it was classified as a pathogenic mutation. Also, it was reported in the Brazilian population [3, 5].
Functional analysis revealed that this mutation leads to expression of C-terminally truncated α/β-subunit precursor protein. The transcript level of the nonsense mutation p.R587X mRNA was decreased by 40%, suggesting that these mutant mRNAs are unstable. This premature termination led to loss of ER exit signals in the cytoplasmic domain of the β-subunit and therefore it is retained in the ER, S1P-mediated proteolytic activation is inhibited which in turn caused the complete loss of GlcNAc-1-phosphotransferase activity. This was consistent with the severe phenotype associated with this mutation in homozygous pattern .
A novel frameshift mutation of 1 bp deletion in exon 19 (c.3488_3488delC; p.T1163KfsX2) was detected in homozygous pattern in a female patient who was a product of consanguineous parents. The patient presented at birth with coarse facies and skeletal deformities. Recurrent upper respiratory tract infections and delayed mental and motor milestones were the main complaints. The patient also showed brachycephaly, anteriorly bowed tibia and fibula, flared lower ribs, right side inguinal hernia, and mild atrophic brain changes were reported in the brain CT. Her clinical picture suggested a severe form of ML II. On DNA level, the C-base deletion changed threonine at position 1163 into lysine and led to a premature stop codon two amino acids away from the deletion site (p.T1163KfsX2). This change occurred in the conserved Stealth domain of β-subunit (from amino acid 1149 to 1185), which has been proposed to mediate the catalytic function of GlcNAc-1-phosphotransferase. ML II severe forms are caused by frameshift and nonsense mutations. Thus, a frameshift mutation in such important domain most probably be damaging and is responsible for the phenotype observed in our patient. According to American College of Medical Genetics and Genomics (ACMG) standards and guidelines, this variant is considered as a pathogenic variant .
Collectively, although clinical presentations were variable and heterogeneous among the studied group, yet they were compatible with the expected biochemical, E.M., and molecular findings. The detected increased activities of β-Hexosaminindase-A in extracellular matrices among the studied group are in agreement with the known biochemical pathogenesis of ML II. The E.M. findings in turn conformed to both clinical, biochemical, and molecular diagnosis in all patients .
These results suggest that the detected mutations in this study affected the assembly and function of α/β subunits in ML II patients. In turn, this led to defective activity of GlcNAc-1-phosphotransferase enzyme. β-Hexosaminindase-A is one of the affected lysosomal enzymes by this defect as it requires M6P marker for proper targeting to lysosomes. As predicted, this defect propagated to the characteristic clinical presentations and E.M picture found in the patients under study. The molecular findings were able to confirm the predicted effect of each mutation on the protein, and hence establish a promising correlation between the 4 stages of diagnosis.
The study included 8 patients, which is a reasonable sample size for such rare disorder and single-center referrals.
In conclusion, 62.5% of the mutation carrying alleles (10/16 alleles) among the studied patients had the same mutation; c.3503_3504delTC (p.L1168QfsX5). This may signify the frequency of this mutation as a common disease causing variant for the ML II Egyptian patients. The high rate of parental consanguinity in our population increases the occurrence of homozygous mutations in probands. Prenatal diagnosis of ML is accurately confirmed by molecular studies in families with previously affected siblings. The quaternary diagnostics scheme of ML II should include clinical assessment, biochemical evaluation of enzymes, E.M examination of gingival inclusion bodies, and molecular study of GNPTAB gene.
A future study on a larger group of ML II patients to determine the frequency of ML II and III among Egyptian patients is recommended. Since ML II is rare and usually misdiagnosed, employment of GNPTAB gene molecular analysis among the first line diagnostic battery is to be considered along with lysosomal enzyme activity assay.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
American College of Medical Genetics and Genomics
Limb Malformations & Skeletal Dysplasia Clinic
- ML II:
Mucolipidosis type II
Aggarwal S, Francisca M, Dalal AB, Mohamed SJ, Jain N, João M, Alves S (2014) Prenatal skeletal dysplasia phenotype in severe MLII alpha/beta with novel GNPTAB mutation. Gene 542(2):266–268. https://doi.org/10.1016/j.gene.2014.03.053
Bargal R, Zeigler M, Abu-libdeh B, Zuri V, Mandel H, Ben-Neriah Z, Stewart F, Elcioglu N, Hindi T, Le Merrer M, Bach G, Raas-Rothschild A (2006) When mucolipidosis III meets mucolipidosis II: GNPTA gene mutations in 24 patients. Mol Genet Metab 88(4):359–363. https://doi.org/10.1016/j.ymgme.2006.03.003
Cathey S, Leroy G, Wood T, Eaves K, Simensen R, Kudo M, Stevenson R, Friez M (2010) Phenotype and genotype in Mucolipidoses II and III alpha/beta: a study of 61 Probands. J Med Genet 47(1):38–48. https://doi.org/10.1136/jmg.2009.067736
Coutinho M, Encarnaҫão M, Gomes R, Santos L, Martins S, Sirois-Gagnon D, Bargal R, Filocamo M, Raas-Rothschild A, Tappino B, Laprise C, Cury G, Schwartz I, Artigalãs O, Prata M, Alves S (2011) Origin and spread of a common deletion causing mucolipidosis type II: insights from patterns of haplotypic diversity. Clin Gen 80(3):273–280. https://doi.org/10.1111/j.1399-0004.2010.01539.x
Cury G, Matte U, Artigalas O, Alegra T, Velho R, Sperb F, Burin M, Ribeiro E, Lourenco C, Kim C, Valadares E, Galera M, Acosta A, Schwartz I (2013) Mucolipidosis II and III alpha/beta in Brazil: analysis of the GNPTAB gene. Gene 524(1):59–64. https://doi.org/10.1016/j.gene.2013.03.105
Encarnaҫão M, Lacerda L, Costa R, Prata M, Coutinho M, Ribeiro H, Lopes L, Pineda M, Ignatius J, Galvez H, Mustonen A, Vieira P, Lima M, Alves S (2009) Molecular analysis of the GNPTABB and GNPTG genes in 13 patients with mucolipidosis type II or type III - identification of eight novel mutations. Clin Genet 76(1):76–84. https://doi.org/10.1111/j.1399-0004.2009.01185.x
Hakim M, Walia H, Krishna S, Tobias J (2017) Anesthetic management of a 13-year-old adolescent with mucolipidosis type II for total hip arthroplasty. Journal of Med Cases 8(7):203–206. https://doi.org/10.14740/jmc2834w
Kasapkara Ç, Akçaboy M, Eroğlu F, Derİnkuyu B (2018) Mucolipidosis type III: a rare disease in differential diagnosis of joint stiffness in pediatric rheumatology. Arch Rheumatol 33(1):93–98. https://doi.org/10.5606/ArchRheumatol.2018.6262
Kazemi N, Estiar MA, Fazilaty H, Sakhinia E (2018) Variants in GNPTAB, GNPTG and NAGPA genes are associated with stutterers. Gene 647:93–100. https://doi.org/10.1016/j.gene.2017.12.054
Kerr D, Memoli V, Cathey S, Harris B (2011) Mucolipidosis type III α/β: the first characterization of this rare disease by autopsy. Arch Pathol Lab Med 135(4):503–510. https://doi.org/10.5858/2010-0236-CR.1
Kollmann K, Pestka JM, Ku SC, Schweizer M, Scho E, Karkmann K, Otomo T, Catala-Lehnen P, Failla AV, Marshall RP, Krause M, Santer R, Amling M, Braulke T, Schinke T (2013) Decreased bone formation and increased osteoclastogenesis cause bone loss in mucolipidosis II. EMBO Mol Med 12:1871–1886
Kollmann K, Pohl S, Marschner K, Encarnaҫão M, Sakwaa I, Tiede S, Poorthuis B, Lübked T, Müller-Loennies S, Storch S, Braulke T (2010) Mannose phosphorylation in health and disease. Eur J Cell Biol 89(1):117–123. https://doi.org/10.1016/j.ejcb.2009.10.008
Kolter T, Sandhoff K (2005) Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Ann Rev Cell Dev Biol 21(1):81–103. https://doi.org/10.1146/annurev.cellbio.21.122303.120013
Kudo M, Brem M, Canfield W (2006) Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha / beta -subunits precursor gene. Am J Hum Genet 78:4515–4563
Laradi S, Tukel T, Khediri S, Shabbeer J, Erazo M, Chkioua L, Chaabouni M, Ferchichi S, Miled A, Desnick R (2006) Mucopolysaccharidosis type IV: N-acetylgalactosamine-6-sulfatase mutations in Tunisian patients. Mol Genet Metab 87(3):213–218. https://doi.org/10.1016/j.ymgme.2005.11.001
Liu S, Zhang W, Shi H, Yao F, Wei M, Qiu Z (2016) Mutation analysis of 16 mucolipidosis II and III alpha/beta Chinese children revealed genotype-phenotype correlations. Plos One 11:1–12
Pasumarthi D, Gupta N, Sheth J, Jain J, Rungsung I, Kabra M, Ranganath P, Aggarwal S, Phadke S, Girisha K, Shukla A, Datar C, Verma I, Dua Puri R, Bhavsar R, Mistry M, Sankar V, Gowrishankar K, Agrawal D, Nair M, Danda S, Prakash Soni J, Dalal A (2020) Identification and characterization of 30 novel pathogenic variations in 69 unrelated Indian patients with mucolipidosis type II and type III. J Hum Genet 65(11):971–984. https://doi.org/10.1038/s10038-020-0797-8
Plante M, Claveau S, Lepagec P, Lavoie E, Brunet S, Roquis D, Morin C, Vézina LC (2008) Mucolipidosis II: a single causal mutation in the N -acetylglucosamine-1- phosphotransferase gene (GNPTAB) in a French Canadian founder population. Clin Genet 72:236–244
Qian Y, Lee I, Lee W, Qian M, Kudo M, Canfield W, Lobel P (2010) Functions of the α, β, and γ Subunits of UDP-GlcNAc: Lysosomal Enzyme N-Acetylglucosamine-1-phosphotransferase. J Biol Chem 285(5):3360–3370. https://doi.org/10.1074/jbc.M109.068650
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30
Schweizer M, Markmann S, Braulke T, Kollmann K (2013) Ultrastructural analysis of neuronal and non-neuronal lysosomal storage in mucolipidosis type II knock-in mice. Ultrastruct Pathol 37(5):366–372. https://doi.org/10.3109/01913123.2013.810687
Singh A, Prasad R, Gupta AK, Sharma A, Alves S, Coutinho M, Kapoor S, Mishra O (2017) I-cell disease (mucolipidosis II Alpha/Beta): from screening to molecular diagnosis. Indian J Pediatr 84(2):144–146. https://doi.org/10.1007/s12098-016-2243-7
Tappino B, Chuzhanova N, Regis S, Dardis A, Corsolini F, Stroppiano M, Tonoli E, Beccari T, Rosano C, Mucha J, Blanco M, Szlago M, Di Rocco M, Cooper D, Filocamo M (2009) Molecular characterization of 22 novel transferase α - and β -subunit (GNPTAB) gene mutations causing mucolipidosis types II α / β and III α / β in 46 patients. Hum Mutat 973:956–973
Velho R, Ludwig N, Alegra T, Sperb-ludwig F, Guarany N, Matte U, Schwartz I (2016) Enigmatic in vivo GlcNAc-1-phosphotransferase (GNPTG) transcript correction to wild type in two mucolipidosis III gamma siblings homozygous for nonsense mutations. J Hum Genet 61(6):555–560. https://doi.org/10.1038/jhg.2016.13
Velho R, Pace R, Klünder S, Sperb-ludwig F, Lourenço C, Schwartz I, Braulke T, Pohl S (2015) Analyses of disease-related GNPTAB mutations de fi ne a novel GlcNAc-1-phosphotransferase interaction domain and an alternative site-1 protease cleavage site. Hum Mol Genet 24(12):3497–3505. https://doi.org/10.1093/hmg/ddv100
Velho R, Harms F, Danyukova T, Ludwig N, Friez M, Cathey S, Filocamo M, Tappino B, Güneş N, Tüysüz B, Tylee K, Brammeier K, Heptinstall L, Oussoren E, van der Ploeg A, Petersen C, Alves S, Saavedra G, Schwartz I, Muschol N, Kutsche K, Pohl S (2019) The lysosomal storage disorders mucolipidosis type II, type III alpha/beta, and type III gamma: Update on GNPTAB and GNPTG mutations. Hum Mutat 40(7):842–864
Wang Y, Ye J, Qiu W, Han L, Gao X, Liang L, Gu X, Zhang H (2019) Identification of predominant GNPTAB gene mutations in Eastern Chinese patients with mucolipidosis II/III and a prenatal diagnosis of mucolipidosis II. Acta Pharmacol Sin 40(2):279–287. https://doi.org/10.1038/s41401-018-0023-9
Yang M, Cho SY, Park H, Choi R, Kim Y, Kim J, Lee SY, Ki CS, Kim JW, Sohn YB, Song J, Jin DK (2017) Clinical, biochemical and molecular characterization of Korean patients with mucolipidosis II / III and successful prenatal diagnosis. Orphanet J Rare Dis 12:1–9
Yang Y, Wu J, Liu H, Chen X, Wang Y, Zhao M, He X (2013) Genomics Two homozygous nonsense mutations of GNPTAB gene in two Chinese families with mucolipidosis II alpha / beta using targeted next-generation sequencing. Genomics 102(3):169–173. https://doi.org/10.1016/j.ygeno.2013.06.001
We thank the STDF (Science and Technology Development Fund in Egypt) for funding this work as part of Centers of Scientific Excellence grants [project number 5253; entitled: recent advances in the diagnosis, management and research of genetic diseases].
This work was supported by The Science and Technology Development Fund (STDF) [project number 5253]. The authors confirm independence from the sponsors; the sponsors have not influenced the content of the article.
Ethics approval and consent to participate
The Medical Research Ethical Committee at the Host Research Centre approved the study protocol, and written informed consents were taken from all individuals’ legal guardians involved in the study. Reference number is not available.
Consent for publication
Consent for publication of the information was obtained from the legal guardians of all patients involved according to the guidelines of The Medical Research Ethical Committee at the NRC.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Essawi, M.L., Fateen, E.M., Atia, H.A. et al. Quaternary diagnostics scheme for mucolipidosis II and detection of novel mutation in GNPTAB gene. J Genet Eng Biotechnol 19, 111 (2021). https://doi.org/10.1186/s43141-021-00204-4
- GNPTAB gene
- ML II